A Phase 2/3 Multicenter, Randomized, Placebo-Controlled,Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis.

Trial Profile

A Phase 2/3 Multicenter, Randomized, Placebo-Controlled,Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PURSUIT-IV
  • Most Recent Events

    • 15 May 2013 FDA approved golimumab [SIMPONI] for the treatment for adult patients with moderately to actively severe ulcerative colitis, based on data from the PURSUIT trials, according to a Janssen Biotech media release.
    • 07 May 2013 New source identified and integrated: ClinicalTrials.gov record NCT01842152 sponsored by Janssen.
    • 07 May 2013 New source identified and integrated: ClinicalTrials.gov record NCT01842152 sponsored by Janssen.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top